Properties of pramlintide and insulin upon mixing

What Was Tested

This randomized controlled trial looks at Amylin (Islet Amyloid Polypeptide).

Who Took Part

The age groups tagged for this paper are teenagers, adults, middle-aged adults and older adults, both men and women.

In two randomized, open-label, placebo-controlled, five-period-crossover studies, patients with type 1 DM received preprandial injections of pramlintide, short-acting insulin, and long-acting insulin administered either by separate injections or after mixing in various combinations.

How the Study Was Run

In design terms this was a randomized, open-label, placebo-controlled and crossover study.

Because people in this Amylin (Islet Amyloid Polypeptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Being open-label, the Amylin (Islet Amyloid Polypeptide) study did not mask who received what.

Some participants received a placebo instead of Amylin (Islet Amyloid Polypeptide), giving a reference point.

Each person switched between Amylin (Islet Amyloid Polypeptide) and the comparison at some point, usually with a gap in between.

What Was Measured

PubMed files the paper under topics including Amyloid, Area Under Curve, Diabetes Mellitus, Type 1, Drug Combinations, Insulin, Islet Amyloid Polypeptide and United States.

What This Means in Plain Language

The paper is a randomized, open-label and placebo-controlled study of Amylin (Islet Amyloid Polypeptide).

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2005 (American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists), a journal based in England.

More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.